Tenpoint Therapeutics
Tenpoint is a biotechnology company committed to advancing engineered cell-based therapies and in vivo reprogramming to restore vision for people with degenerative ocular diseases. The company is addressing the ultimate cause of vision loss by replacing diseased cells with healthy ones to permanently restore vision.
Sector
Biopharmaceuticals
Strategy
Capital
Website
www.tenpointtherapeutics.com
Related News
Tenpoint Therapeutics announces positive topline data from Phase 3 pivotal study, BRIO-II, of BRIMOCHOL™ PF for the treatment of presbyopia
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. join forces, building the next era of best-and first-in-class ophthalmic medicines
Tenpoint Therapeutics launches with $70 million Series A financing to reverse vision loss through engineered cell-based therapeutics and in vivo reprogramming
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.